Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 24;15(2):e0229145.
doi: 10.1371/journal.pone.0229145. eCollection 2020.

Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes

Anne-Caroline Jeannin  1   2 , Joe-Elie Salem  1   3   4   5 , Ziad Massy  6 , Carole Elodie Aubert  7   8 , Cees Vermeer  9 , Chloé Amouyal  1   2   5 , Franck Phan  1   2   5   10 , Marine Halbron  1   2   5 , Christian Funck-Brentano  1   3   4   5 , Agnès Hartemann  1   2   5   10 , Olivier Bourron  1   2   5   10
Affiliations

Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes

Anne-Caroline Jeannin et al. PLoS One. .

Erratum in

Abstract

Aims/hypothesis: Diabetic peripheral neuropathy is a frequent and severe complication of diabetes. As Matrix-gla-protein (MGP) is expressed in several components of the nervous system and is involved in some neurological disease, MGP could play a role in peripheral nervous system homeostasis. The aim of this study was to evaluate factors associated with sensitive diabetic neuropathy in Type 2 Diabetes, and, in particular, dephospho-uncarboxylated MGP (dp-ucMGP), the inactive form of MGP.

Methods: 198 patients with Type 2 Diabetes were included. Presence of sensitive diabetic neuropathy was defined by a neuropathy disability score (NDS) ≥6. Plasma levels of dp-ucMGP were measured by ELISA.

Results: In this cohort, the mean age was 64+/-8.4 years old, and 80% of patients were men. Peripheral neuropathy was present in 15.7% of the patients and was significantly associated (r = 0.51, p<0.0001) with dp-ucMGP levels (β = -0.26, p = 0.045) after integrating effects of height (β = -0.38, p = 0.01), insulin treatment (β = 0.42, p = 0.002), retinopathy treated by laser (β = 0.26, p = 0.02), and total cholesterol levels (β = 0.3, p = 0.03) by multivariable analysis.

Conclusions: The association between diabetic neuropathy and the inactive form of MGP suggests the existence of new pathophysiological pathways to explore. Further studies are needed to determine if dp-ucMGP may be used as a biomarker of sensitive neuropathy. Since dp-ucMGP is a marker of poor vitamin K status, clinical studies are warranted to explore the potential protective effect of high vitamin K intake on diabetic peripheral neuropathy.

PubMed Disclaimer

Conflict of interest statement

A patent has been filed on a method using circulating Matrix Gla protein measurement for diagnosis and treating peripheral neuropathies by Assistance Publique Hôpitaux de Paris - APHP). Olivier Bourron, Joe-Elie Salem and Agnès Hartemann are the inventors. The application number is 18306503.6 – 1118. Status of application: recorded. The patent specific aspect of manuscript covered in patent application: use of circulating Matrix Gla protein measurement for diagnosis and treating peripheral neuropathies. This study was supported by a fund from Lilly Company. The company was involved neither in the design of the study nor in data collection. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

References

    1. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019. January;42(Suppl 1):S124–S38. 10.2337/dc19-S011 - DOI - PubMed
    1. Forsblom CM, Sane T, Groop PH, Totterman KJ, Kallio M, Saloranta C, et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia. 1998. November;41(11):1253–62. 10.1007/s001250051062 - DOI - PubMed
    1. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990. May;13(5):513–21. 10.2337/diacare.13.5.513 - DOI - PubMed
    1. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev Diabet Stud. 2015 Spring-Summer;12(1–2):48–62. - PMC - PubMed
    1. Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature. Diabetes Res Clin Pract. 2015. August;109(2):215–25. 10.1016/j.diabres.2015.04.031 - DOI - PubMed

Publication types